As of 2024-12-13, the Relative Valuation of C4 Therapeutics Inc (CCCC) is (33.89) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.32 USD, the upside of C4 Therapeutics Inc based on Relative Valuation is -884.4%.
The range of the Relative Valuation is (31.32) - (29.05) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.0x - 31.3x | 26.2x |
| Forward P/E multiples | 19.0x - 19.4x | 19.2x |
| Fair Price | (31.32) - (29.05) | (33.89) |
| Upside | -825.1% - -772.5% | -884.4% |
| Date | P/E |
| 2024-12-12 | -2.86 |
| 2024-12-11 | -3.15 |
| 2024-12-10 | -2.88 |
| 2024-12-09 | -2.80 |
| 2024-12-06 | -2.96 |
| 2024-12-05 | -2.61 |
| 2024-12-04 | -2.62 |
| 2024-12-03 | -2.72 |
| 2024-12-02 | -2.88 |
| 2024-11-29 | -3.04 |
| 2024-11-27 | -3.04 |
| 2024-11-26 | -2.80 |
| 2024-11-25 | -2.93 |
| 2024-11-22 | -2.84 |
| 2024-11-21 | -2.68 |
| 2024-11-20 | -2.71 |
| 2024-11-19 | -2.78 |
| 2024-11-18 | -2.81 |
| 2024-11-15 | -2.88 |
| 2024-11-14 | -3.16 |
| 2024-11-13 | -3.43 |
| 2024-11-12 | -3.69 |
| 2024-11-11 | -3.93 |
| 2024-11-08 | -4.05 |
| 2024-11-07 | -4.04 |
| 2024-11-06 | -3.99 |
| 2024-11-05 | -4.07 |
| 2024-11-04 | -4.32 |
| 2024-11-01 | -3.75 |
| 2024-10-31 | -3.57 |
| 2024-10-30 | -3.70 |
| 2024-10-29 | -3.95 |
| 2024-10-28 | -4.01 |
| 2024-10-25 | -3.94 |
| 2024-10-24 | -3.98 |
| 2024-10-23 | -4.04 |
| 2024-10-22 | -4.16 |
| 2024-10-21 | -4.18 |
| 2024-10-18 | -4.25 |
| 2024-10-17 | -4.29 |
| 2024-10-16 | -4.68 |
| 2024-10-15 | -4.22 |
| 2024-10-14 | -3.93 |
| 2024-10-11 | -3.65 |
| 2024-10-10 | -3.55 |
| 2024-10-09 | -3.39 |
| 2024-10-08 | -3.43 |
| 2024-10-07 | -3.45 |
| 2024-10-04 | -3.60 |
| 2024-10-03 | -3.57 |